Trial Profile
Use of CXCL9 as a Biomarker of Acthar Efficacy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary) ; Corticotropin (Primary)
- Indications Sarcoidosis
- Focus Biomarker; Therapeutic Use
- 10 May 2023 Status changed from not yet recruiting to recruiting.
- 23 Mar 2020 Planned initiation date changed from 1 Dec 2019 to 1 Oct 2020.
- 15 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Dec 2019.